DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

DE

460.88

+0.05%↑

CTAS

198.8

-0.16%↓

FDX

240.24

-0.95%↓

PAYX

126.51

-0.29%↓

CPRT

44.93

+1.65%↑

Search

Ocugen Inc

Gesloten

1.78 1.71

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.76

Max

1.87

Belangrijke statistieken

By Trading Economics

Inkomsten

611K

-15M

Verkoop

-108K

1.4M

Winstmarge

-1,073.489

Werknemers

95

EBITDA

724K

-13M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+367.03% upside

Dividenden

By Dow Jones

Volgende Winsten

7 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

138M

456M

Vorige openingsprijs

0.07

Vorige sluitingsprijs

1.78

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ocugen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2025, 16:58 UTC

Winsten

BMW Trims 2025 View, Citing Weaker Performance in China

7 okt 2025, 23:43 UTC

Marktinformatie

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 okt 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 okt 2025, 23:19 UTC

Marktinformatie

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 okt 2025, 22:40 UTC

Marktinformatie

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 20:44 UTC

Populaire aandelen

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 okt 2025, 19:42 UTC

Marktinformatie

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 okt 2025, 19:23 UTC

Acquisities, Fusies, Overnames

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 okt 2025, 19:07 UTC

Marktinformatie

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 okt 2025, 19:02 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 okt 2025, 15:33 UTC

Marktinformatie

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 okt 2025, 15:25 UTC

Marktinformatie

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 okt 2025, 15:15 UTC

Marktinformatie

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 okt 2025, 15:04 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

7 okt 2025, 15:04 UTC

Marktinformatie

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 okt 2025, 14:52 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Ocugen Inc Prognose

Koersdoel

By TipRanks

367.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.5 USD  367.03%

Hoogste 15 USD

Laagste 4 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ocugen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.6818 / 0.74Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat